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Introduction
Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, devel-
oped for the treatment of autoimmune diseases and for
the prevention of transplant rejection. Thanks to its selec-
tive action on proliferating cells, Tofa can offer a way to
block T cell activation. The potential field of clinical appli-
cation is thus represented by disorders with inappropriate
T cell response, such as rheumatoid arthritis, psoriasis,
graft rejection, ulcerative colitis and graft versus host
disease. However, the tuning of efficacy (suppression of
pathogenic lymphocytes) and safety (suppression of pro-
tective immunity) remains an open issue.
Unexpectedly, whereas the drug has been widely used
in animal models and has been already introduced into
the clinics, only few studies had investigated its immu-
nological potential in vitro.
Objectives
To study the effect of tofacitinib in vitro stimulated
lymphocytes. In particular, to measure the effect of the
drug on cell proliferation, lymphocyte subsets and cell
viability during treatment and after interruption of
treatment.
Methods
Healthy donors’ peripheral blood mononuclear cells are
stimulated or not with phytohemoagglutinin and incu-
bated for 4-days with different concentrations of tofaciti-
nib. After the first incubation, cells are washed twice and
further incubated for 4-days without stimuli and drug.
Cell proliferation is assessed by CFSE dilution assay; cell
viability by 7-AAD staining; lymphocyte subsets are ana-
lyzed by multicolour flow cytometry.
Results
Here we showed that Tofa exerts a rapid and strong effect
on lymphocyte activation, leading to a complete arrest
in proliferation and to a strong down-regulation of activa-
tion markers in PHA stimulated lymphocytes. Notably,
these results are achieved with a negligible toxicity on
lymphocyte viability. However, after the withdrawal of the
drug, stimulated lymphocytes resume proliferation. Thus,
transient treatment with Tofa didn’t lead to a relevant
inhibition of final proliferation, but it strongly affected the
distribution of lymphocyte subsets, with a reduction of NK
cells, B cells and CD8 cells.
Conclusion
Based on these data, we can presume that discontinua-
tion of the drug after a short treatment may lead reacti-
vation of diseased lymphocytes and to a reduction of
NK and B cells as well in vivo, possibly resulting in
undesired effects of the drug. To evaluate this possibi-
lity, a careful study of the expression of lymphocyte acti-
vation markers and of the distribution of lymphocyte
subsets should be performed in all subjects after discon-
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